Zepbound tracker
Your Zepbound tracker, from one shot day to the next
Record each Zepbound shot and where it went, from a pen, a vial or a KwikPen. Answer a short daily check-in and keep your weight, food and fluids beside it. The record is free, and Handle never tells you what dose to take.
On this page
In short
- A Zepbound tracker records each weekly shot (the amount, the day and the injection site) alongside how you feel and your weight trend, so appointments start from facts, not memory.
- Zepbound is tirzepatide from Eli Lilly, a once-weekly injection approved in the US for long-term weight management in adults with obesity, or overweight with a weight-related condition, and for moderate to severe obstructive sleep apnea in adults with obesity.1
- It comes in six strengths from 2.5 mg to 15 mg, as single-dose pens and vials and, since January 2026, as four-dose KwikPens and multi-dose vials.1
- In the 72-week SURMOUNT-1 trial of adults without diabetes, average weight loss was 15.0% to 20.9% depending on the dose, against 3.1% on placebo, counting everyone who started (the treatment-regimen estimand).1,4
- Handle records all of this for free, with no streaks or scores, and never tells you to change, skip or catch up a dose.
What to record in a Zepbound tracker
Keep it small enough to keep up. These details are the hardest to remember later and the most useful at appointments.
- Every shot, as it happened. The amount, the day and the time. A late or missed week belongs in the record too; it is information, not a mark against you.
- Where it went. The label lists the abdomen and thigh, or the back of the upper arm if someone else injects, and asks you to rotate sites with each dose.1
- Which pen or vial. Note the date if you change form, because single-dose and four-dose forms have different storage rules.1
- How you feel. Nausea, diarrhea, constipation, tiredness. In the trials, most people who stopped Zepbound because of side effects did so in the first few months, mainly because of stomach symptoms.1
- Food, fluids and protein. Zepbound reduces appetite and food intake.2 Fluids matter when your stomach is unsettled: the label warns that fluid loss can injure the kidneys.1 See our GLP-1 food tracker guide and our guide to what to eat on Zepbound and Mounjaro.
- Dates that matter. Starting, each dose change, any new medicine. On the contraceptive pill? The label recommends a non-oral method, or an added barrier method, for 4 weeks after starting and after each dose increase.1
Zepbound at a glance
Facts from the US label and the FDA. They describe the product; your prescriber decides the dose. To compare, see Mounjaro vs Zepbound and Foundayo vs Zepbound, or find out whether there is a Zepbound pill.
| Zepbound | |
|---|---|
| Made by | Eli Lilly and Company |
| Medicine | Tirzepatide, which activates two gut-hormone receptors, GIP and GLP-1.1 More in our tirzepatide tracker. |
| Approved in the US for | Long-term weight management in adults with obesity, or overweight with a weight-related condition, and moderate to severe obstructive sleep apnea in adults with obesity, alongside diet and activity1 |
| FDA approval | November 8, 2023 (weight management); December 20, 2024 (sleep apnea)2,3 |
| How it's taken | An injection under the skin once a week, at any time of day, with or without meals1 |
| Strengths | 2.5, 5, 7.5, 10, 12.5 and 15 mg1 |
| Forms | Single-dose pen or vial; four-dose multi-dose vial or KwikPen1 |
| Half-life | About 5 to 6 days in people with overweight or obesity; a steady level after about 4 weeks of weekly doses1 |
| Storage | In the fridge at 2–8 °C (36–46 °F), never frozen. A single-dose pen or vial can stay unrefrigerated, up to 30 °C (86 °F), for 21 days in total.1 |
| UK and EU | There is no Zepbound brand: the same medicine is licensed for weight management as Mounjaro.9,12 See our Mounjaro tracker. |
In Handle
Shot day, logged in a few taps
Set up Zepbound once, with the amount your prescriber set and your shot day. After that, logging is a quick confirmation of the time you injected and the site: abdomen, thigh or upper arm, left or right.
- Amount, time and injection site in one entry
- Each dose in your record lists its site, so rotating is easy to follow
- Forgot to log it? Add it later, up to 30 days back
- Shot-day reminders in the iPhone app
Pens, vials and KwikPens: one record for all of them
Zepbound was approved in November 2023.2 Lilly began selling single-dose vials for self-pay through LillyDirect in August 2024, and in June 2025 announced vials in every strength.5,6 Two four-dose forms, a multi-dose vial and the KwikPen, joined the label in January 2026.1,7
The label says an opened KwikPen or multi-dose vial is thrown away after a total of 30 days at room temperature, 30 days after first use, or four weekly doses, even with medicine left, and that a KwikPen is never shared, even with a new needle.1 Handle's private note for the day is a handy place to write "new KwikPen today".
In Handle
How you feel, in a few taps a day
Handle asks about nausea every day, plus the symptoms you switch on, such as diarrhea or constipation. Add up to six more, like belching and fatigue, both in Zepbound's side-effect table.1 More in our side-effect tracker guide.
Some answers, such as severe nausea, come with a clear next step, like contacting your care team. Handle never diagnoses and is not a monitoring or emergency service; if you feel very unwell, contact your clinician or emergency services yourself.
- The same short card every day, whatever you answer
- A private one-line note for the day that nothing reads
- Missed a day? Fill it in later, up to 30 days back
Side effects to watch on Zepbound
From Zepbound's label: SURMOUNT-1 and SURMOUNT-2, in which 2,519 adults took Zepbound for up to 72 weeks. Each figure is the share of people who reported it.
| Side effect | Placebo | 5 mg | 10 mg | 15 mg |
|---|---|---|---|---|
| Nausea | 8% | 25% | 29% | 28% |
| Diarrhea | 8% | 19% | 21% | 23% |
| Constipation | 5% | 17% | 14% | 11% |
| Vomiting | 2% | 8% | 11% | 13% |
| Stomach pain | 5% | 9% | 9% | 10% |
| Indigestion | 4% | 9% | 9% | 10% |
| Injection-site reactions | 2% | 6% | 8% | 8% |
| Fatigue | 3% | 5% | 6% | 7% |
| Belching | 1% | 4% | 5% | 5% |
Source: Zepbound prescribing information, Table 1.1 Side effects led 4.8% to 6.7% of people on Zepbound to stop, against 3.4% on placebo.1 More in Zepbound side effects.
In Handle
Weeks of Zepbound, side by side
Journey draws your weight as weekly averages with your Zepbound dose as a step line beneath it, beside how you felt, what you ate and drank, and your training. It never claims one explains another.
- No streaks, scores or reminders to weigh
- Resistance and cardio sessions counted separately
- Protein and fluid totals, with a target only if your clinician set one
What the SURMOUNT trials found
All four trials enrolled adults with obesity or overweight. Averages describe large groups, not you, and trials of different people can't be compared directly.
| Trial | Who took part | Length | Average result, Zepbound vs placebo |
|---|---|---|---|
| SURMOUNT-1 | 2,539 adults without diabetes | 72 weeks | Weight −15.0% (5 mg), −19.5% (10 mg), −20.9% (15 mg) vs −3.1%1,4 |
| SURMOUNT-2 | 938 adults with type 2 diabetes | 72 weeks | Weight −12.8% (10 mg), −14.7% (15 mg) vs −3.2%1 |
| SURMOUNT-OSA | Adults with moderate to severe sleep apnea, in two trials | 52 weeks | Breathing interruptions in sleep (AHI) fell by 25.3 and 29.3 an hour, vs 5.3 and 5.51,8 |
| SURMOUNT-4 | 670 adults after 36 weeks on tirzepatide | 52 more weeks | Continuing: a further −5.5%; switched to placebo: +14.0%1 |
SURMOUNT-1 and SURMOUNT-2 figures count everyone randomized, whether or not they kept taking it (the treatment-regimen estimand).1,4 The label's SURMOUNT-4 figures also count everyone randomized at week 36.1 If your weight changes direction, that is a signal to discuss with your prescriber, not a failure. For the head-to-head trial against semaglutide, see Zepbound vs Wegovy.
A week with your Zepbound tracker
There is no right way to do this; here is one ordinary week.
- OncePick your shot day
Agree a day with your prescriber that fits your week. The label allows any time of day, with or without meals.1 Reminders in the iPhone app can mark the day.
- Shot dayLog it while it's fresh
Record the amount and the site as soon as you've injected. Next week, your record shows which site you used.
- Every dayCheck in, and weigh if you like
Ordinary days show what normal looks like for you, and weekly averages mean one heavy morning doesn't dominate your trend.
- If a week goes differentlyRecord what happened
Zepbound's prescribing information and Medication Guide have their own rule for a missed dose, so ask your prescriber or pharmacist. Handle never tells you to catch up.
- Before an appointmentBring the weeks with you
Open Journey together. The consultation report, a Premium feature, is built for this moment: a summary your clinician can read without an account.
Handle PremiumPremium
A summary built for your appointment
The consultation report is a summary for your next visit: your Zepbound record including dose changes, your weight history, symptom summaries, nutrition and activity, and an optional note about what you want to discuss. It helps your clinician see the pattern quickly. More in our guide to preparing for a GLP-1 doctor appointment.
- Shared as a secure link that can be revoked at any time
- Your private daily notes are never included
- Your clinician needs no account
Premium is an optional subscription in the iPhone app.
Choosing a Zepbound tracker: log, sheet or app
Searching for a Zepbound tracking log, journal or spreadsheet? Any of them works if you keep it up; they differ in how much work it takes to turn entries into something readable. Our GLP-1 tracker guide compares apps.
| Paper log or journal | Spreadsheet | Handle | |
|---|---|---|---|
| Shot, time and site | Written by hand | Typed each week | One entry, with your plan filled in |
| Symptoms | Whatever you jot down | A column you fill in | A short daily check-in |
| Weight trend | Numbers on a page | A chart, if you build one | Weekly averages, charted |
| Food, fluids and protein | If you write it down | Another sheet | Daily totals |
| Reminders | None | Set up elsewhere | Dose and check-in reminders in the iPhone app |
| For your prescriber | The notebook itself | Print or share the file | Consultation report link (Premium) |
| Cost | A notebook | Free | Free; some features are Premium |
| Platforms | Wherever you carry it | Any device with the file | iPhone |
A paper log has real strengths: it needs no phone and no account, and it stays entirely private. If you'd like one, our free printable GLP-1 tracker is ready to use. See what Handle's free plan includes.
Questions people ask
Is there a Zepbound tracker app?+
Yes. Handle works with Zepbound: it records each weekly shot and injection site, a short daily check-in, your weight, food and fluids, and a consultation report for your prescriber is among its Premium features. The iPhone app is free to download from the App Store. For other options, see our guide to GLP-1 trackers.
Does Lilly have its own Zepbound app?+
Yes. Eli Lilly's free Lilly Health app says it supports people on Zepbound, Mounjaro or Foundayo. Its App Store listing, seen on September 23, 2026, describes a logbook, dosing reminders and charts to share with your healthcare provider, for US residents aged 18 and over.11 Handle is a separate app that records any GLP-1 medicine.
Is Handle's Zepbound tracker free?+
Yes. Logging shots and injection sites, the daily check-in, weight, food, drinks and activity, and the Journey charts are all free, with no advertising. The Between doses estimate, the consultation report with share links, food photo scanning and iOS widgets are Premium features. You never need them to keep a complete record.
Can I use a spreadsheet as a Zepbound tracker?+
Yes, if you keep it up. Give it columns for the date and time, the amount, the pen or vial, the injection site (left or right), symptoms and how strong they were, weight, and anything new such as a dose change. What a spreadsheet won't do on its own is remind you, chart weekly weight averages, or produce a summary your prescriber can read quickly.
Where should I inject Zepbound?+
Zepbound's label lists the abdomen or thigh, or the back of the upper arm if another person gives the injection, and says to rotate injection sites with each dose.1 Handle records the site, left or right, with every shot, so your record shows where you went last time. If one area keeps reacting, mention it to your care team.
How long does Zepbound stay in your system?+
Tirzepatide's half-life is about five to six days in people with overweight or obesity, and a steady level builds after about four weeks of weekly doses.1 Handle's Between doses view, a Premium feature, estimates your level from the doses you recorded. It is a model, not a blood test, and it only draws doses you have already taken. Our guide to the Zepbound and Mounjaro half-life explains what the labels say.
Is Zepbound the same as Mounjaro?+
They contain the same medicine, tirzepatide, made by Eli Lilly. In the US, Zepbound is approved for weight management and sleep apnea, and Mounjaro for type 2 diabetes.1,10 In the UK and EU there is no Zepbound brand, and Mounjaro carries the weight-management license.9,12 Compare them in Mounjaro vs Zepbound.
Sources
- Eli Lilly and Company, via DailyMed (U.S. National Library of Medicine). Zepbound (tirzepatide) injection — Prescribing Information, effective August 28, 2026.
- U.S. Food and Drug Administration. FDA Approves New Medication for Chronic Weight Management, November 8, 2023.
- U.S. Food and Drug Administration. FDA Approves First Medication for Obstructive Sleep Apnea, December 20, 2024.
- Jastreboff AM et al., New England Journal of Medicine 2022;387:205-216. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1), 2022.
- Eli Lilly and Company, via PR Newswire. Lilly releases Zepbound® (tirzepatide) single-dose vials, expanding supply and access for adults living with obesity, August 27, 2024.
- Eli Lilly and Company, via PR Newswire. Lilly to offer all approved doses of Zepbound (tirzepatide) single-dose vials through LillyDirect Self Pay Pharmacy Solutions, June 16, 2025.
- Eli Lilly and Company, via PR Newswire. Zepbound (tirzepatide), the most prescribed weight management medication in 2025, now available in multi-dose KwikPen, February 23, 2026.
- Malhotra A et al., New England Journal of Medicine 2024;391:1193-1205. Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity (SURMOUNT-OSA), 2024.
- Medicines and Healthcare products Regulatory Agency (UK). MHRA authorises diabetes drug Mounjaro (tirzepatide) for weight management and weight loss, November 8, 2023.
- Eli Lilly and Company, via DailyMed (U.S. National Library of Medicine). Mounjaro (tirzepatide) injection — Prescribing Information, effective August 27, 2026.
- Eli Lilly and Company, via Apple App Store (US). Lilly Health™ — App Store listing, seen September 23, 2026.
- European Medicines Agency. Mounjaro — European public assessment report.
Written by the Handle team from the sources above, last checked on September 24, 2026. How we write: our editorial policy. Spotted something out of date? Tell us at [email protected].
Handle supports recording and conversations with your care team. It does not diagnose, and it never tells you to start, change, skip or stop a dose. This page is general information, not medical advice. Always follow your prescriber and your medicine's instructions for use.